AIM share code: SKIN

16 September 2020

Integumen PLC

("Integumen" or "Company")

Rule 2.9 Announcement - update

In accordance with Rule 2.9 of the Code:

Integumen confirms that, as at the date of this announcement, following the share consolidation which became effective today, it has 113,185,643 ordinary shares of 0.1 pence each in issue and admitted to trading on AIM under the new International Securities Identification Number ("ISIN") GB00BMGWZY29.

In addition, as a result of the share consolidation there are 4,585,214 unlisted warrants with an exercise price of 20 pence per ordinary share and an exercise period until 2 May 2021. These warrants are freely transferable and were issued on 2 May 2019.

In addition, there are 440,000 unlisted warrants with an exercise price of 15 pence per ordinary share and an exercise period until 5 January 2023. These warrants are freely transferable and were issued on 5 January 2018.

In addition, there are 1,890,502 unlisted warrants with an exercise price of 25.7868 pence per ordinary share and an exercise period until 15 September 2024. These warrants are freely transferable and were issued on 15 September 2020.

For further information please contact:

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 648

SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END